Investigation of usability and efficacy of loratadine rapidly disintegrating tablets (Claritin® Reditabs®)

Masutaka Furue, Shinichi Imafuku

研究成果: ジャーナルへの寄稿評論記事

抄録

A questionnaire survey on the usability and efficacy of loratadine rapidly disintegrating tablets (Claritin® Reditabs®) was conducted in 64 patients with pruritic skin disease (17 with urticaria, 25 with atopic dermatitis, and 22 with other eczema/dermatitis). Regarding overall ease of ingestion, 54 patients (84.4%) considered it "good", 9 (14.1%) "neither good nor bad", and 0 (0%) "bad". Eleven patients (17.2%) sometimes "forgot to take" the drug and 53 (82.8%) did not forget to take the drug, with a significantly lower number of patinets "forgetting to take" the drug. Fifty-four patients (84.4%) stated that they wanted to continue the drug. The reasons for wanting to continue it (with multiple answers allowed) included "it is convenient to take the drug anywhere" for 28 patients (43.8%), "no need for water" for 25 (39.1%), and "once-daily ingestion" for 23 (35.9%). It was found that the rapidly disintegrating tablet dosage form improved drug compliance.

元の言語英語
ページ(範囲)195-198
ページ数4
ジャーナルNishinihon Journal of Dermatology
68
発行部数2
DOI
出版物ステータス出版済み - 5 29 2006

Fingerprint

Loratadine
Tablets
Pharmaceutical Preparations
Eating
Eczema
Urticaria
Dosage Forms
Dermatitis
Atopic Dermatitis
Skin Diseases
Water

All Science Journal Classification (ASJC) codes

  • Dermatology

これを引用

Investigation of usability and efficacy of loratadine rapidly disintegrating tablets (Claritin® Reditabs®). / Furue, Masutaka; Imafuku, Shinichi.

:: Nishinihon Journal of Dermatology, 巻 68, 番号 2, 29.05.2006, p. 195-198.

研究成果: ジャーナルへの寄稿評論記事

@article{fa774cbb938e41f7b463418362a1ea90,
title = "Investigation of usability and efficacy of loratadine rapidly disintegrating tablets (Claritin{\circledR} Reditabs{\circledR})",
abstract = "A questionnaire survey on the usability and efficacy of loratadine rapidly disintegrating tablets (Claritin{\circledR} Reditabs{\circledR}) was conducted in 64 patients with pruritic skin disease (17 with urticaria, 25 with atopic dermatitis, and 22 with other eczema/dermatitis). Regarding overall ease of ingestion, 54 patients (84.4{\%}) considered it {"}good{"}, 9 (14.1{\%}) {"}neither good nor bad{"}, and 0 (0{\%}) {"}bad{"}. Eleven patients (17.2{\%}) sometimes {"}forgot to take{"} the drug and 53 (82.8{\%}) did not forget to take the drug, with a significantly lower number of patinets {"}forgetting to take{"} the drug. Fifty-four patients (84.4{\%}) stated that they wanted to continue the drug. The reasons for wanting to continue it (with multiple answers allowed) included {"}it is convenient to take the drug anywhere{"} for 28 patients (43.8{\%}), {"}no need for water{"} for 25 (39.1{\%}), and {"}once-daily ingestion{"} for 23 (35.9{\%}). It was found that the rapidly disintegrating tablet dosage form improved drug compliance.",
author = "Masutaka Furue and Shinichi Imafuku",
year = "2006",
month = "5",
day = "29",
doi = "10.2336/nishinihonhifu.68.195",
language = "English",
volume = "68",
pages = "195--198",
journal = "Nishinihon Journal of Dermatology",
issn = "0386-9784",
publisher = "Kyushu University, Faculty of Science",
number = "2",

}

TY - JOUR

T1 - Investigation of usability and efficacy of loratadine rapidly disintegrating tablets (Claritin® Reditabs®)

AU - Furue, Masutaka

AU - Imafuku, Shinichi

PY - 2006/5/29

Y1 - 2006/5/29

N2 - A questionnaire survey on the usability and efficacy of loratadine rapidly disintegrating tablets (Claritin® Reditabs®) was conducted in 64 patients with pruritic skin disease (17 with urticaria, 25 with atopic dermatitis, and 22 with other eczema/dermatitis). Regarding overall ease of ingestion, 54 patients (84.4%) considered it "good", 9 (14.1%) "neither good nor bad", and 0 (0%) "bad". Eleven patients (17.2%) sometimes "forgot to take" the drug and 53 (82.8%) did not forget to take the drug, with a significantly lower number of patinets "forgetting to take" the drug. Fifty-four patients (84.4%) stated that they wanted to continue the drug. The reasons for wanting to continue it (with multiple answers allowed) included "it is convenient to take the drug anywhere" for 28 patients (43.8%), "no need for water" for 25 (39.1%), and "once-daily ingestion" for 23 (35.9%). It was found that the rapidly disintegrating tablet dosage form improved drug compliance.

AB - A questionnaire survey on the usability and efficacy of loratadine rapidly disintegrating tablets (Claritin® Reditabs®) was conducted in 64 patients with pruritic skin disease (17 with urticaria, 25 with atopic dermatitis, and 22 with other eczema/dermatitis). Regarding overall ease of ingestion, 54 patients (84.4%) considered it "good", 9 (14.1%) "neither good nor bad", and 0 (0%) "bad". Eleven patients (17.2%) sometimes "forgot to take" the drug and 53 (82.8%) did not forget to take the drug, with a significantly lower number of patinets "forgetting to take" the drug. Fifty-four patients (84.4%) stated that they wanted to continue the drug. The reasons for wanting to continue it (with multiple answers allowed) included "it is convenient to take the drug anywhere" for 28 patients (43.8%), "no need for water" for 25 (39.1%), and "once-daily ingestion" for 23 (35.9%). It was found that the rapidly disintegrating tablet dosage form improved drug compliance.

UR - http://www.scopus.com/inward/record.url?scp=33646777147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646777147&partnerID=8YFLogxK

U2 - 10.2336/nishinihonhifu.68.195

DO - 10.2336/nishinihonhifu.68.195

M3 - Review article

AN - SCOPUS:33646777147

VL - 68

SP - 195

EP - 198

JO - Nishinihon Journal of Dermatology

JF - Nishinihon Journal of Dermatology

SN - 0386-9784

IS - 2

ER -